Showing 2,061 - 2,080 results of 48,330 for search '(( 50 ((nn decrease) OR (((mean decrease) OR (a decrease)))) ) OR ( 12 we decrease ))', query time: 0.66s Refine Results
  1. 2061
  2. 2062
  3. 2063
  4. 2064

    Flow diagram of the study population. by Dina Evyana (18462048)

    Published 2024
    “…MetS was found in 64.3% of patients. Patients with a PASI score>10 had a significantly higher risk of metabolic syndrome compared to those with a score ≤ 10 (78.6% vs 50%, OR 3.667; 95% CI 1.413–9.514; <i>p</i> = 0.006). …”
  5. 2065
  6. 2066

    Gene clustering identifies up- and down-regulated groups that control development, pluripotency, and cell division. by Michael Shelton (382572)

    Published 2019
    “…<p>Pluripotent H9 hESCs were differentiated for 50 days as previously described [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0222946#pone.0222946.ref012" target="_blank">12</a>], beginning with high (7.5 μM or 10 μM) CHIR99021 concentrations. mRNA samples from the indicated time points were subjected to gene expression profiling. …”
  7. 2067
  8. 2068
  9. 2069
  10. 2070
  11. 2071
  12. 2072
  13. 2073
  14. 2074
  15. 2075
  16. 2076
  17. 2077
  18. 2078
  19. 2079

    IDD388 Polyhalogenated Derivatives as Probes for an Improved Structure-Based Selectivity of AKR1B10 Inhibitors by Alexandra Cousido-Siah (777034)

    Published 2016
    “…Next, by means of IC<sub>50</sub> measurements, X-ray crystallography, WaterMap analysis, and advanced binding free energy calculations with a quantum-mechanical (QM) approach, we have studied their structure–activity relationship (SAR) against both enzymes. …”
  20. 2080

    Data Sheet 1_Reduced hemolytic complement activity in the classical pathway (CH50) is a risk factor for poor clinical outcomes of patients with infections: a retrospective analysis... by Hiroyuki Koami (3878434)

    Published 2025
    “…</p>Results<p>Of 2,726 patients who met the inclusion criteria, logistic regression models demonstrated that decreased CH50 is a significant predictor of 180-day mortality (OR: 0.98-0.99). …”